- Company
- 'Keytruda+Padcev' proposed as a new standard trt for MIBC
- by Hwang, byoung woo Oct 20, 2025 06:07am
- Keytruda (pembrolizumab) and Padcev (enfortumab vedotin) have demonstrated synergistic effects in muscle-invasive bladder cancer (MIBC), opening up new possibilities. Analysis suggests that the combination of enfortumab vedotin and pembrolizumab may shift the perioperative standard of care for MIBC patients who are ineligible for or refuse ci
- Company
- Alecensa achieves 81-month median overall survival
- by Hwang, byoung woo Oct 20, 2025 06:07am
- Roche's ALK inhibitor Alecensa (alectinib) has demonstrated long-term survival benefits exceeding 7 years in patients with ALK-positive advanced non-small cell lung cancer (NSCLC). In the final overall survival (OS) analysis of the Phase III ALEX study, Alecensa showed a clear survival benefit over existing treatments, reaffirming its status
- Company
- Ipsen's Bylvay is officially launched in Korea
- by Son, Hyung Min Oct 20, 2025 06:06am
- &160;Ipsen Korea is introducing a treatment for progressive familial intrahepatic cholestasis (PFIC), an extremely rare hereditary liver disease, to the domestic market. This launch opens new hope for pediatric patients who previously had no treatment option beyond liver transplantation. Bylvay has been selected as the first product unde
- Company
- Rosuzet and K-CAB maintain dual lead…Paxlovid sales surge
- by Chon, Seung-Hyun Oct 17, 2025 06:18am
- Homegrown drugs continue to dominate the top ranks of the outpatient prescription market. Quarterly outpatient prescriptions of the new combination therapy Rosuzet and the new drug K-CAB both surpassed KRW 50 billion, firmly maintaining a two-top system. Meanwhile, Livalozet continued its steep growth trajectory, and Paxlovid saw a sharp rise in
- Company
- DLBCL drug Monjuvi may be prescribed at Big 5 Hospitals
- by Eo, Yun-Ho Oct 17, 2025 06:11am
- Handok's newly introduced drug ‘Monjuvi’ may now be prescribed at tertiary hospitals in Korea. According to industry sources, Monjuvi (tafasitamab), a treatment for diffuse large B-cell lymphoma (DLBCL) introduced by Handok from Incyte, has passed the Drug Committee (DC) reviews at the Big 5 medical institutions in Korea - Samsung Medic
- Company
- "Switzerland and Korea partner up for bio-ecosystem"
- by Son, Hyung Min Oct 17, 2025 06:11am
- As the global pharmaceutical industry is restructuring around collaboration, Switzerland and South Korea are strengthening their partnership to build an innovation ecosystem. The vision is to establish a model of joint innovation, based on efficient resource and mutual trust, rather than a simple technology exchange. On October 16, Roche
- Company
- Expanded reimb prospect for 5 indications of 'Tevimbra'
- by Eo, Yun-Ho Oct 16, 2025 06:21am
- The cancer immunotherapy 'Tevimbra' is gathering attention over whether it will receive expanded reimbursement following its previous success in the esophageal cancer indication. According to industry sources, five indications for BeOneMedicines Korea's PD-1 inhibitor immunotherapy Tevimbra (tislelizumab) are expected to be considered by
- Company
- ‘Leclaza combo extends survival without chemotherapy’
- by Son, Hyung Min Oct 15, 2025 11:37am
- “The MARIPOSA study is the first clinical trial to significantly extend overall survival using two targeted therapies without chemotherapy. Discussions on EGFR-mutated lung cancer treatment will now shift to focus on overall survival.” During a recent interview with Dailypharm, Professors Byoung Chul Cho and Sun Min Lim of Yonsei Cancer
- Company
- Will the MM drug Elrexfio be reimbursed this time?
- by Eo, Yun-Ho Oct 15, 2025 06:12am
- Whether progress will be made for the new multiple myeloma drug Elrexfio (elranatamab) in its second attempt to secure reimbursement in Korea is gathering attention. According to industry sources, Pfizer Korea's bispecific antibody therapy Elrexfio (elranatamab) is expected to be submitted for reimbursement review to the Health Insurance
- Company
- GSK’s myelofibrosis drug Omjjara faces reimb hurdles
- by Eo, Yun-Ho Oct 14, 2025 06:41am
- The reimbursment of GSK’s new myelofibrosis drug Omjjara has become uncertain in Korea. According to Dailypharm coverage, the reimbursement application for GSK Korea's myelofibrosis treatment Omjjara (momelotinib), which had passed the Cancer Disease Deliberation Committee of the Health Insurance Review and Assessment Service (HIRA) in M
